IL2 and type 1 diabetes mellitus: Longitudinal analysis showed that each ld-IL-2 treatment (day 7 and day 42) resulted in an increased percentage of FOXP3+ T cells for all the patients from the TILT trial compared with Treg-T1D patients (Figure 4B).